HSBC downgrades Eli Lilly, questioning obesity-pill hype and Zepbound cash sales

HSBC downgraded Eli Lilly's stock from "hold" to "reduce" on Tuesday morning, and the drugmaker's shares have fallen more than 7% since ^[1]. The note from analyst Rajesh Kumar questioned how much of Lilly's expected growth — especially from a coming obesity pill — is already priced in ^[1]. It stood out because sell-side skepticism about Lilly had been nearly absent, and Lilly was the only large company whose rating HSBC changed in its latest industry review ^[1].

Kumar cut his price target on Lilly to $850 from $1,070 ^[1]. He cited pricing pressure and rising competition in the obesity market, and told Bloomberg that the market is "overexcited" about orforglipron, Lilly's experimental oral GLP-1 ^[1]. Assuming an early summer launch, analysts expect orforglipron to generate between $1.1 billion and $1.3 billion in sales this year ^[1].

"There's a potential for disappointment," Kumar said. "Compliance and persistence on orals can be potentially lower than on injectables. It sort of is a risk, the way the Street is thinking about this." ^[1]

Lilly shares fell 5.9% on Tuesday, making the stock the second-worst performer in the S&P 500 that day, according to MarketWatch ^[2]. FiercePharma put the decline since the downgrade at more than 7% ^[1]. The two figures describe different windows, and the exact closing level was not reported in either account ^[1][2].

Novo Nordisk, Lilly's main competitor, is cutting prices on its GLP-1 products, Kumar said, adding that "there's a slight risk that the pricing environment might not be supportive" ^[1]. He also pointed to a longer-term concern: generic competition for Novo's Ozempic and Wegovy (semaglutide) that could "collapse" pricing in the obesity market. This month, generics companies in India began launching cheaper copycat versions of Novo's semaglutide products ^[1]. Those launches are in India; no generic semaglutide has been reported as launching in the United States ^[1].

HSBC also expects a smaller overall market than most analysts. The consensus projection is $150 billion by 2032, while HSBC puts it at $80 billion to $120 billion ^[1]. Kumar noted the gap between the two companies' own 2026 guidance: Lilly projects roughly a 25% revenue increase at the midpoint, while Novo expects sales to fall 5% to 13% ^[1].

"At this juncture, people are sort of penciling in [a] stairway to heaven kind of growth in Lilly and a complete collapse at Novo," Kumar said. "But the market is joined at the hip and that seems to be missing from the market's thinking." ^[1]

MarketWatch reported a second thread in the downgrade: analysts questioned how durable Zepbound's cash-pay business is ^[2]. The article said the drug's out-of-pocket buyers are often middle-class Americans, and raised the possibility that those sales could weaken if buyers lose jobs ^[2]. What else HSBC said about cash-pay demand has not been disclosed.

Why it matters for patients

This is a stock analyst's view of a company's valuation, not a finding about how well or safely any medicine works ^[1][2]. Nothing in the downgrade changes what the FDA has approved, what insurers cover, or what a prescription costs today.

Even so, the note points to two forces that could eventually reach patients' wallets: competition and pricing. Novo is already cutting prices, and cheaper generic semaglutide is launching in India ^[1]. Whether that pressure spreads to US cash-pay or list prices — and by how much — has not been reported ^[1][2].

The cash-pay question matters most to people who buy these drugs without insurance. MarketWatch raised the idea that out-of-pocket demand could soften if middle-class buyers face job losses ^[2]. That is a hypothesis about future demand, not a statement about current supply or availability.

What happens next

Lilly is expected to launch orforglipron in early summer, with analysts projecting $1.1 billion to $1.3 billion in first-year sales ^[1]. HSBC's assessment came inside an industry review covering companies' second-quarter prospects ^[1]. The two companies' 2026 revenue guidance — about a 25% increase for Lilly and a 5% to 13% decline for Novo — will be tested as the year goes on ^[1].